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Abstract
Background: Mitochondrial trifunctional protein (MTP) and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
deficiency are long-chain fatty acid oxidation disorders with particularly high morbidity and mortality. Outcome can
be favorable if diagnosed in time, prompting the implementation in newborn screening programs. Sporadic cases
missed by the initial screening sample have been reported. However, little is known on pitfalls during confirmatory
testing resulting in fatal misconception of the diagnosis.
Results: We report a series of three patients with MTP and LCHAD deficiency, in whom diagnosis was missed by
newborn screening, resulting in life-threatening metabolic decompensations within the first half year of life. Two
of the patients showed elevated concentrations of primary markers C16-OH and C18:1-OH but were missed by
confirmatory testing performed by the maternity clinic. A metabolic center was not consulted. Confirmatory testing
consisted of analyses of acylcarnitines in blood and organic acids in urine, the finding of normal excretion of
organic acids led to rejection and underestimation of the diagnosis, respectively. The third patient, a preterm
infant, was not identified in the initial screening sample due to only moderate elevations of C16-OH and C18:1-OH
and normal secondary markers and analyte ratios.
Conclusion: Our observations highlight limitations of newborn screening for MTP/LCHAD deficiency. They confirm
that analyses of acylcarnitines in blood and organic acids in urine alone are not suitable for confirmatory testing
and molecular or functional analysis is crucial in diagnosing MTP/LCHAD deficiency. Mild elevations of primary
biomarkers in premature infants need to trigger confirmatory testing. Our report underscores the essential role of
specialized centers in confirming or ruling out diagnoses in suspicious screening results.
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Background
Deficiencies of the mitochondrial trifunctional protein
(MTP) (OMIM# 609015) are autosomal recessively
inherited disorders of long-chain fatty acid oxidation
with an estimated frequency of 1:140,000 [1–3]. MTP is
an octameric multienzyme complex, which is composed
of 4 alpha and 4 beta subunits encoded by the HADHA
and HADHB gene, respectively. It harbors three enzyme
activities: long-chain enoyl-CoA hydratase, long-chain
3-hydroxyacyl-CoA dehydrogenase (LCHAD), and long-
chain 3-ketoacyl-CoA thiolase (LCKAT) catalyzing the last
three steps of long-chain fatty acid oxidation [4–7].
General MTP deficiency is characterized by reduced activ-
ities of all three MTP enzymes [1]. The most common de-
fect of the MTP complex, however, is isolated LCHAD
deficiency (LCHADD) (OMIM# 609016), which is defined
by reduced LCHAD activity with substantial preservation
of the other two MTP enzyme activities [2]. Both MTP
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deficiency and isolated LCHADD lead to an accumu-
lation of toxic ß-oxidation intermediates causing acute
symptoms as well as long-term complications. Clinical
symptoms mainly develop during periods of illness or
fasting and affect organs preferring long-chain fat as
primary source of energy, such as heart and skeletal
muscle. Encephalopathy, hypoketotic hypoglycemia,
lactic acidosis, and liver dysfunction are mostly found.
Long-term complications comprise recurrent episodes
of metabolic derangement, recurrent episodes of rhabdo-
myolysis, cardiomyopathy, feeding difficulties, peripheral
neuropathy, and retinopathy [8–10].
Untreated, MTP and LCHAD deficiency is associ-
ated with particularly high morbidity and mortality [8,
10]. Therapy aims to prevent catabolic episodes indu-
cing endogenous long-chain fatty acid oxidation as
well as to restrict the intake of exogenous long-chain
fatty acids [11, 12]. Further treatment options such as
anaplerotic therapy with heptanoate are under evalu-
ation [13]. Treated in time, outcome of MTP/LCHAD
deficiency can be favorable [9, 14], prompting the in-
clusion of MTP and LCHAD deficiency into newborn
screening programs [15, 16]. Method of choice is the
determination of acylcarnitines by tandem mass spec-
trometry (MS/MS) with 3-hydroxypalmitoylcarnitine
(C16-OH) and 3-hydroxyoleoylcarnitine (C18:1-OH)
as primary biomarkers [17]. Of note, by MS/MS the
different defects of MTP cannot be distinguished [18].
The finding of a positive newborn screening result is
no definitive diagnosis. It is an indication of a child at
risk and triggers confirmatory testing. Approaches for
confirmatory testing may vary between centers. They
include second screening in dried blood spot, analysis
of acylcarnitines in plasma, and determination of organic
acids in urine. Subsequently, enzyme analysis in fibro-
blasts, and genetic analysis are performed in different
centers [16, 18, 19]. Confirmatory testing for long-chain
fatty acid disorders has proven to be challenging. For
very-long-chain acyl-CoA dehydrogenase deficiency
(VLCADD), the most common long-chain fatty oxida-
tion defect, it has been postulated that reliable diagnosis
by MS/MS newborn screening may not be possible [20].
Missed cases due to normal or only slightly elevated
VLCADD-specific biomarkers have been described
[20–25] resulting in the recommendation of prompt
genetic or enzymatic testing whenever VLCADD is sus-
pected [16]. Furthermore, acylcarnitine profiles from
healthy newborns during postnatal catabolism inducing
fatty acid oxidation can indistinguishably imitate acyl-
carnitine profiles of VLCADD patients resulting in a
well-known high incidence of false-positive cases in
newborn screening [20].
In contrast to VLCADD, no significant rate of
false-positive or false-negative cases seems to occur in
screening for MTP/LCHAD deficiency [18]. Sporadic
cases missed by the initial newborn screening sample have
been reported [9, 19, 26]. The general performance of
newborn screening regarding sensitivity, specificity, and
positive predictive value has been reported for several pro-
grams with false-negative and false-positive cases leading
to a modification of analyte cut-off values, the implemen-
tation of analyte ratios, or second-tier strategies [20, 25].
However, little is known on pitfalls during confirmatory
testing resulting in fatal misconception of the diagnosis.
We report a series of three missed cases with MTP and
LCHAD deficiency. One case was missed by misinterpret-
ing the initial screening sample due to prematurity. Two
cases were missed by inappropriate management of con-
firmatory testing and the failure to refer the patients to a
specialized metabolic center. We wish to raise awareness
that MTP/LCHAD deficiency may be missed in newborn
screening and to underscore the essential role of special-
ized metabolic centers in confirming or rejecting the diag-
nosis in suspicious screening results.
Methods
Patients
We retrospectively collected data of 3 living patients
with MTP or LCHAD deficiency cared for in a German
(Munich; patient 1 and 2) and an Austrian (Salzburg;
patient 3) metabolic center. Data of all three patients
were reviewed at their respective metabolic center and
are reported anonymized. The study is in accordance
with the guidelines of the local ethical committees. The
parents of all three subjects provided written informed
consent.
Biomarker analysis
Analysis of acylcarnitines was performed as part of the
newborn screening program in dried blood spots. Blood
samples were collected by the maternity clinic on filter
paper as recommended between day 2 and day 3. MS/MS
was performed as described previously [27]. In accordance
with regulatory guidelines in Germany, positive screening
results were reported to the sender (i.e. the maternity
clinic) who communicated the results to the parents. The
senders were explicitly advised by the screening laboratory
to seek advice from metabolic experts about timely con-
firmatory testing and medical care [28].
For analysis of acylcarnitines in plasma, blood samples
were collected in tubes prepared with lithium-heparin.
Plasma was separated by centrifugation within one hour
after sampling. Samples were stored at 4 °C until analysis.
Analysis was performed using tandem mass spectrometry.
Organic acids were analyzed in urine using capillary
gas chromatography followed by mass spectrometry as
described before [29].
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Functional and molecular analyses
Enzyme activity was measured in cultured fibroblasts
harvested by skin biopsy. Enzyme assay for LCHAD
and LCKAT was performed by a standardized procedure
as described before [30, 31]. Molecular analysis of the en-
coding HADHA (GenBank: NM_000182) and HADHB
(GenBank: NM_000183) genes were performed by Sanger
sequencing [8].
Results
Clinical findings
Clinical data of the three patients are summarized in
Table 1, metabolic and genetic data in Table 2.
Patient 1, a boy, was born after 35 weeks of gestation by
Caesarian section due to maternal HELLP (haemolysis, el-
evated liver enzymes, low platelet count) syndrome (birth
weight 2120 g). Postnatal adaptation was uneventful. He is
the second child of healthy, non-consanguineous parents
of Caucasian origin (Germany/Romania). His older
brother is healthy. Two former pregnancies of the mother
ended in abortions (G4P2).
Newborn screening was performed on day 2, showing
elevated concentrations of C16-OH (1.62 μmol/l;
cut-off < 0.05 μmol/l) and C18:1-OH (0.46 μmol/l;
cut-off < 0.04 μmol/l). A second screening specimen
collected on day 11 again showed elevated C16-OH
(0.49 μmol/l; cut-off < 0.05 μmol/l) and C18:1-OH
(0.29 μmol/l; cut-off < 0.04) compatible with MTP/
LCHAD deficiency (Table 2). Additionally, an analysis
of organic acids in urine was initiated revealing normal
results. Based on the normal excretion of organic acids,
the diagnosis of MTP/LCHAD deficiency was consid-
ered excluded, and the patient was discharged home
from the maternity clinic. A metabolic center had not
been contacted.
At the age of 4 months, after an episode of vomiting
and reduced food intake, the patient suffered a life--
threatening metabolic decompensation. He presented with
hypoglycemia, lactic acidosis (lactate 5 mmol/l; reference
< 2.1 mmol/l), hyperammonemia (188 μmol/l; reference <
55 μmol/l), hepatopathy (aspartate transaminase 176 U/l,
reference < 70 U/l; alanine transaminase 141 U/l, refer-
ence < 49 U/l; lactate dehydrogenase 1101 U/l, reference
< 570 U/l), and severe hypertrophic cardiomyopathy
(N-terminal brain natriuretic peptide 13,445 ng/l; refer-
ence < 84 ng/l). He was comatose when admitted to the
emergency department of a metabolic center. The pa-
tient’s mother recalled the suspicious newborn screening
result enabling prompt anabolic treatment including the
restriction of long-chain fatty acids. However, the cardio-
vascular situation initially worsened to cardiogenic shock
requiring invasive ventilation and catecholamine treat-
ment. He recovered slowly after treatment in an intensive
care unit for more than three weeks. A percutaneous
endoscopic gastrostomy (PEG) tube was inserted for con-
tinuous feeding at night time and during catabolic situa-
tions. In addition, a vascular access port system was
implanted due to difficult peripheral venous access.
At the time of metabolic decompensation, analysis
of acylcarnitines in plasma again revealed a pattern
consistent with MTP/LCHAD deficiency with ele-
vated concentrations of C16-OH (15.41 μmol/l;
cut-off < 0.17 μmol/l) and C18:1-OH (10.67 μmol/l;
cut-off < 0.1 μmol/l) (Table 2). Urine analysis now
showed elevated excretion of dicarboxylic acids. Diagnosis
of LCHAD deficiency was confirmed by analysis of
enzyme activity in fibroblasts revealing a reduced activity
of LCHAD (4 nmol/min x mg protein; reference 34–
114 nmol/min x mg) and a normal activity of LCKAT. Se-
quencing of the HADHA gene identified the prevalent
mutation, c.1528G >C (p.E510Q), in a homozygous state
(Table 2) [32–34] .
Patient 1 is now 7 years of age attending regular school.
He is on a fat-modified diet strictly reduced in natural
(long-chain) fat, enriched with medium-chain triglycerides
(MCT), and supplemented with essential fatty acids. He
receives continuous feeding during nights over a PEG
tube. It was possible to terminate oral medication for car-
diac insufficiency one year after metabolic decompensa-
tion. As a long-term complication of LCHAD deficiency,
he has been diagnosed with early-stage retinopathy.
Patient 2, a boy, was born after 39 weeks of gestation
(birth weight 2750 g). Pregnancy and postnatal adapta-
tion were uneventful. He is the third child of healthy,
Table 1 Summary of clinical and laboratory findings of the
patients
Patient 1 Patient 2 Patient 3
Relevant medical history
Pregnancy HELLP uneventful HELLP
Gestational age 35 39 29
Features of metabolic decompensation
Age (months) 4 8 5
Hypoglycemia + – –
Lactic acidosis + – +
Hyperammonemia + – n. a.
Hepatopathy + – +
Cardiomyopathy + + +
Rhabdomyolysis – – +
Long term complications
Cardiomyopathy – – –
Rhabdomyolysis – – +
Retinopathy + – +
Symbols and abbreviations are as follows: n. a. = not available, + = present, −=not
present, HELLP: hemolysis elevated liver enzymes low platelet count
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non-consanguineous parents descending from Afghanistan.
His older brother and sister are healthy.
Newborn screening was performed on day 2, showing
elevated concentrations of C16-OH (0.35 μmol/l;
cut-off < 0.05 μmol/l) and C18:1-OH (0.06 μmol/l;
cut-off < 0.04 μmol/l) suspicious for MTP/LCHAD de-
ficiency. A second screening sample collected on day 7
confirmed the elevations of C16-OH (0.44 μmol/l;
cut-off < 0.05 μmol/l) and C18:1-OH (0.08 μmol/l;
cut-off < 0.04 μmol/l). Analysis of organic acids in urine
showed normal results (Table 2). Despite the recom-
mendations of the newborn screening laboratory, pa-
tient 2 was not referred to a metabolic center, and
dietary treatment was not initiated. The parents were
informed by the maternity clinic to ensure regular food
intake and to present to the primary care doctor at an
early stage in case of intercurrent illness. At the age of
2 months, patient 2 was seen at the maternity clinic for
clinical and biochemical follow-up. At that time, pa-
tient 2 was in good health. The acylcarnitine pattern
was again suspicious for MTP/LCHAD deficiency, ana-
lysis of organic acids in urine showed an elevated ex-
cretion of dicarboxylic acids. Patient 2 was not referred
to a metabolic center but was followed by the maternity
clinic. At 4 months of age, echocardiography showed
symmetric hypertrophy of the cardiac septum. Dietary
restriction of long-chain fatty acids and supplementa-
tion of medium chain triglycerides (MCT) were initiated.
Compliance to treatment was poor. No contact to a meta-
bolic center was made. At 8 months of age, patient 2 pre-
sented with progressive dilatative cardiomyopathy and
clinical signs of heart insufficiency. Eventually, he was
transferred to a metabolic center. Adequate treatment was
started immediately with continuous feeding via PEG
tube, strict reduction of long-chain fatty acids intake, sup-
plementation of MCT, and oral medications for cardiac
insufficiency. Under this treatment, patient 2 improved,
and his cardiac function fully recovered.
At the time of first admission to a metabolic center,
the concentrations of C16-OH (0.045 μmol/l; reference
< 0.01 μmol/l) and C18:1-OH (0.055 μmol/l; reference
< 0.01 μmol/l) in plasma were elevated. Molecular ana-
lysis of the HADHB gene revealed two novel mutations
(c.1198G > T/c.442 + 663A > G) in a heterozygous state
(Table 2). Mutation c.1198G > T (p.E400X) is predicted
to result in a premature stop and is absent in the
Exome Aggragation Consortium (ExAC, accessed 20
Feb 2018). The transition c.442 + 663A > G in intron 7
has been postulated to show a similar pathogenic
mechanism as the described transition c.422 + 614A >
G. This transition has been shown to result in a cryptic
splice donor spot with insertion of intronic sequences
and a premature stop codon [35, 36]. In combination,
these variants most likely will lead to nonsense medi-
ated mRNA decay and finally absence of protein. Test-
ing the patient’s parents for the identified HADHB
mutations in order to prove the heteroallelic state was
not covered by the health care system due to the refu-
gee status of the family. To our knowledge, however,
there are no reports of symptomatic MTP heterozy-
gotes. Furthermore, molecular analysis of the HADHA
gene did not reveal any mutations. Given the clinical
and biochemical phenotype of the patient we strongly
assume the mutations identified in the HADHB gene to
be heteroallelic, thus confirming the diagnosis of MTP
deficiency.
Table 2 Biomarkers and genetic data of the patients
Age Acylcarnitines [μmol/l] Dicarboxylic
Acids in
Urine
Molecular Genetics
C16-OH (c) C18:1-OH (c)
Patient 1 HADHA gene: c.1528G > C (p.E510Q),
homozygous
2 daysa 1.62 (< 0.05) 0.46 (< 0.04)
11 daysa 0.49 (< 0.05) 0.29 (< 0.04) normal
4 monthsb 15.41 (< 0.17) 10.67 (< 0.10) elevated
Patient 2 HADHB gene: c.1198G > T (p.E400X)/
c.442 + 663A > G, compound heterozygous
2 daysa 0.35 (< 0.05) 0.06 (< 0.04)
7 daysa 0.44 (< 0.05) 0.08 (< 0.04) normal
8 monthsb 0.045 (< 0.01) 0.055 (< 0.01) elevated
Patient 3 HADHA gene: c.1528G > C (p.E510Q),
homozygous
5 daysa 0.31 (< 0.12) 0.47 (< 0.16) n.a.
5 monthsb 0.98 (< 0.10) 0.74 (< 0.10) elevated
Symbols and abbreviations are as follows: a filter paper, b plasma, collected in metabolic decompensation, ccut-off, n.a. = not available
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The patient is now 4 years of age. He is on a fat-modified
diet and receives continuous feeding during nights over a
PEG tube. It was possible to terminate oral medication for
cardiac insufficiency one year after initial decompensation.
So far, he experienced no long-term complications from
MTP deficiency.
Patient 3, a boy, is the third child of healthy, non-consan-
guineous parents of Caucasian origin (Austria). His older
brother and sister are healthy. One former pregnancy of the
mother ended in an abortion (G4P3). He was born after
29 weeks of gestation by urgent Caesarian section due to
maternal HELLP syndrome (birth weight 1040 g). He
required non-invasive ventilation for 3 days (FiO2 0.21)
due to respiratory distress syndrome and received ana-
leptic treatment with caffeine until day 19 of life. Paren-
teral nutrition was administered for 8 days. In addition,
age-appropriate enteral nutrition was introduced.
Newborn screening was performed on day 5 and consid-
ered normal. Retrospective review revealed that concen-
trations of C16-OH (0.31 μmol/l; cut-off < 0.12 μmol/l)
and C18:1-OH (0.47 μmol/l; cut-off < 0.10 μmol/l) were
moderately elevated (Table 2) but did not prompt further
diagnostic work-up due to normal secondary markers and
normal analyte ratios. A second screening specimen after
14 days of life, recommended for infants prior to 32 weeks
of gestation, was not obtained for unknown reasons.
At 5 months of age, patient 3 suffered a severe meta-
bolic decompensation after an episode of vomiting and
reduced food intake. He presented with mild lactic acid-
osis (3.6 mmol/l; reference < 2.1 mmo/l), hepatopathy
(aspartate transaminase 614 U/l, reference 10–50 U/L; ala-
nine transaminase 266 U/l, reference 6–53 U/l; partial
thromboplastin time 178 s, reference 28–43 sec; pro-
thrombin time 47%, reference 70–130%; fibrinogen
83 mg/dl, reference 150–380 mg/dl; antithrombin III 51%,
reference 84–124%), rhabdomyolysis (creatine kinase
485 U/l; reference 41–330 U/l) and dilated cardiomyop-
athy (N-terminal brain natriuretic peptide 5468 ng/l; refer-
ence < 84 ng/l). The patient was admitted to a metabolic
center. Biomarker analysis showed elevated concentra-
tions of C16-OH (0.98 μmol/l; cut-off < 0.10 μmol/l) and
C18:1-OH (0.74 μmol/l; cut-off < 0.10 μmol/l) in plasma
(Table 2) as well as elevated excretion of dicarboxylic acids
in urine. Anabolic treatment including MCT supplemen-
tation, strict restriction of long-chain fatty acids, as well
as oral medications for cardiac insufficiency were initi-
ated immediately. Under this treatment, the patient
fully recovered.
Diagnosis of LCHAD deficiency was confirmed by
molecular analysis of the HADHA gene revealing the
prevalent mutation, c.1528G > C (p.E510Q), in a homo-
zygous state (Table 2) [32–34]. Patient 3 is now 9 years
of age. He is on a fat-modified diet and receives con-
tinuous feeding during nights over a PEG tube. It was
possible to terminate oral medication for cardiac insuf-
ficiency one year after initial decompensation. Despite
good compliance to treatment, he suffered from mul-
tiple episodes of rhabdomyolysis. In addition, he has
been diagnosed with retinopathy. This patient was pre-
viously described by Karall et al. [9].
Discussion
The performance of MS/MS screening programs and
screening for single disorders including missed cases
have been reported [18, 20, 25, 37]. However, little is
known about pitfalls during confirmatory testing result-
ing in fatal misconception of the diagnosis.
We describe three missed cases in newborn screening
for MTP/LCHAD deficiency, two of whom were missed
during confirmatory diagnostic work-up. All three pa-
tients experienced severe metabolic decompensation,
two of them life-threatening.
Patient 1 and 2 showed newborn screening results
which were clearly indicative for MTP/LCHAD deficiency.
Confirmatory testing was initiated by the maternity clinic
and consisted of repeat analysis of acylcarnitines in dried
blood spots and the determination of organic acids in
urine on day 11 and day 7 of life, respectively. Despite ab-
normal acylcarnitines, the finding of a normal excretion of
organic acids led to a rejection of MTP/LCHAD defi-
ciency in patient 1 and an underestimation of the diagno-
sis and its clinical consequences in patient 2. However,
most patients with fatty acid disorders show normal excre-
tion of organic acids when well. The MTP/LCHAD-char-
acteristic excretion of 3-hydroxydicarboxylic acids without
or only small ketonuria is mostly seen during fasting and
illness. False-negative results in patients with LCHADD
have been reported [10]. Nevertheless, the determination
of acylcarnitines in blood and organic acids in urine was
recommended as initial follow-up analyses by newborn
screening programs in the past [16, 38]. Current guide-
lines recommend prompt functional or molecular analyses
as first line MTP/LCHAD deficiency confirmation exclu-
sive of further biochemical parameters [3, 39]. LCHADD
is the most common defect in disorders of the MTP com-
plex [18] and is associated with the prevalent mutation
c.1528G >C (p.E510Q) in the HADHA gene affecting up
to 91% of defective alleles [8, 10, 32, 33]. Thus, molecular
analysis is the method of choice. Enzyme testing is
performed only in single laboratories, and fibroblasts are
generally required. It is therefore less feasible, but may
be essential in establishing the diagnosis in patients
with equivocal genetic results, i.e. novel mutations and
heterozygotes.
The responsible physicians in the maternity clinic of
both patient 1 and 2 decided against referring the patients
to a metabolic center or at least seeking metabolic special-
ists’ advice. Hence, they did not initiate the appropriate
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confirmatory testing and, moreover, misinterpreted the re-
sults in patients with a high suspicion of a condition with
a considerable risk of severe decompensation. Though not
mandatory, referral of newborns with suspicious screening
results, or consulting a metabolic specialist to discuss the
screening results and actions to be taken, is explicitly rec-
ommended in newborn screening guidelines [3, 16, 28].
Notably, for LCHADD it has been reported that immedi-
ate metabolic advice is crucial for the survival of newborns
detected by newborn screening. The majority of deaths
occurs before or within 3 weeks of diagnosis, especially in
patients with limited approach to metabolic expertise [10].
Our report underscores the essential role of specialized
metabolic centers in confirming or rejecting the diagnosis
in suspicious screening results.
In patient 3, the moderately elevated concentrations of
C16-OH and C18:1-OH in the initial newborn screening
sample were regarded normal, presumably due to the
patient’s prematurity [9]. The history of patient 3 adds to
the discussion whether cut-off ranges in newborn
screening may be applied for term and preterm new-
borns. Whereas previous data suggested that equal
cut-offs may be applied [40, 41], it recently has been
shown that concentrations of acylcarnitines were lower
in healthy preterm compared to term newborns [42].
Many reasons have been postulated, including endogen-
ous and metabolic differences due to lower birth weight
and immaturity, and the effect of treatments adminis-
tered in newborn intensive care units [42]. A nearly
missed case of VLCADD probably due to dextrose infu-
sion masking the characteristic primary markers has
been reported [24]. Considering this, the moderately ele-
vated biomarkers in preterm patient 3 may have been a
consequence of increased anabolism. Our observation
underlines the limitations when performing and evaluat-
ing newborn screening in preterm populations. Further
studies are necessary to evaluate the need for different
cut-offs in these newborns to reduce the risk of
false-negative results. Moreover, the routine analysis of a
second screening specimen at a later point in time, as
required for infants born prior to 32 weeks of gestation
in most screening programs in the United States and
Europe including Austria [19, 28, 39], might have added
to reduce the risk of missing the diagnosis in patient 3
[24]. The reason why no second screening specimen was
obtained from patient 3 remained unclear.
Otherwise, the medical history of prematurity in com-
bination with maternal HELLP syndrome could have fa-
cilitated the diagnosis in patient 1 and patient 3. In
patients with MTP/LCHAD deficiency a remarkably
high incidence of prematurity (> 60%) and maternal
HELLP syndrome (approximately 25%) is found [8, 9,
14, 18, 43–45]. As a consequence, the finding of even
mildly elevated biomarkers indicative for MTP/LCHAD
deficiency in a premature newborn needs to prompt
confirmatory testing.
Confirmatory testing of a suspicious newborn screening
result does not only aim to prove the diagnosis but like-
wise aims to rule out the screened condition in a newborn.
This applies especially for severe, unpredictable disorders
with high morbidity and a remarkable mortality up to 90%
like MTP/LCHAD deficiency [33].
The review of newborn screening often focusses on reli-
able diagnosis of relevant disease without affecting healthy
individuals. It is well acknowledged that false-positive
screening results do impose an unnecessary and high bur-
den on health care systems and families. False-positive
screening results have been associated with parental
anxiety, stress, depression, altered parent-child relation-
ship, and persistent misconception of ill health in the child
who required follow-up testing [46, 47]. However, the
experience of a life-threatening decompensation due to a
formerly suspected disorder that was missed by insuffi-
cient confirmatory testing or misconception of the diag-
nostic work-up, severely traumatizes parents and might
flaw the reputation of newborn screening.
Conclusions
MTP/LCHAD deficiency has been implemented in many
newborn screening programs. We describe two cases of
LCHADD and one of MTP deficiency which were missed
by either newborn screening or confirmatory testing. Two
patients experienced life-threatening decompensations,
one progressive cardiomyopathy. Our report highlights
that the analyses of acylcarnitines in blood and urinary
organic acids alone are not sufficient for confirmatory
testing in MTP/LCHAD deficiency. Molecular or func-
tional analysis is mandatory to confirm or rule out MTP/
LCHAD deficiency. Even mild elevations of primary bio-
markers in premature infants need to trigger confirmatory
testing. Taking into account prematurity and maternal
HELLP syndrome as aspects of medical history might fa-
cilitate the evaluation of screening results in MTP/
LCHAD deficiency. Our report strongly emphasizes the
recommendation that patients with suspicious newborn
screening results should immediately be referred to spe-
cialized centers.
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